Recombinant Human Matriptase/ST14 Catalytic Domain, CF

Catalog # Availability Size / Price Qty
3946-SEB-010
Recombinant Human Matriptase/ST14 Catalytic Domain Enzyme Activity
1 Image
Product Details
Citations (15)
FAQs
Supplemental Products
Reviews (3)

Recombinant Human Matriptase/ST14 Catalytic Domain, CF Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<1.0 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to cleave the fluorogenic peptide substrate Boc-QAR-AMC (Catalog # ES014). The specific activity is >10,000 pmol/min/μg, as measured under the described conditions.
Source
E. coli-derived human Matriptase/ST14 protein
Gly596-Val855, with an N-terminal Met and 6-His tag
The protein was purified, auto-activated and further purified.
Accession #
N-terminal Sequence
Analysis
Val615
Predicted Molecular Mass
26 kDa
SDS-PAGE
27 kDa (major) and minor auto-activation fragments, reducing conditions

Product Datasheets

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

3946-SEB

Formulation Supplied as a 0.2 μm filtered solution in Tris-HCl and Glycerol.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Assay Procedure

Materials
  • Assay Buffer: 50 mM Tris, 50 mM NaCl, 0.01% (v/v) Tween® 20, pH 9.0
  • Recombinant Human Matriptase/ST14 Catalytic Domain (rhMatriptase) (Catalog # 3946-SEB)
  • Substrate:  BOC-Gln-Ala-Arg-AMC (Catalog # ES014), 10 mM stock in DMSO
  • F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
  • Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent
  1. Dilute rhMatriptase to 0.1 µg/mL in Assay Buffer.
  2. Dilute Substrate to 50 µM in Assay Buffer.
  3. Load 50 µL of 0.1 µg/mL rhMatriptase into a plate, and start the reaction by adding 50 µL of 50 µM substrate. Include a Substrate Blank containing 50 µL of Assay Buffer and 50 µL of Substrate.
  4. Read at excitation and emission wavelengths of 380 nm and 460 nm (top read), respectively, in kinetic mode for 5 minutes.
  5. Calculate specific activity:

     Specific Activity (pmol/min/µg) =

Adjusted Vmax* (RFU/min) x Conversion Factor** (pmol/RFU)
amount of enzyme (µg)

  

*Adjusted for Substrate Blank.
**Derived using calibration standard 7-Amino, 4-Methyl Coumarin (AMC) (Sigma, Catalog # A9891).

Per Well:

  • rhMatriptase: 0.005 µg
  • Substrate: 25 µM

Data Image

Enzyme Activity Recombinant Human Matriptase/ST14 Catalytic Domain Enzyme Activity View Larger

Recombinant Human Matriptase is measured by its ability to cleave the fluorogenic peptide substrate Boc-QAR-AMC (Catalog # ES014).

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: Matriptase/ST14

Human matriptase, encoded by the ST14 (suppression of tumorogenicity 14) gene, is also known as tumor associated differentially expressed gene 15 protein/TADG‑15), epithin, and membrane‑type serine protease 1/MT‑SP1 (1). Predicted to have a significant role in tumor biology, matriptase may be a novel target for anti‑cancer therapy (2). However, expressed in most human epithelia, matriptase is also important in several physiological processes (1). For example, it activates prostasin to initiate a protease cascade that is essential for epidermal differentiation (3), and it converts a single‑chain IGFBP-rp1 into the two‑chain form (4). Matriptase is a type II transmembrane serine protease with a complex modular structure (1). The 855 amino acid (aa) sequence of human matriptase consists of a cytoplasmic tail (aa 1‑55), a transmembrane domain (aa 56‑76), and an extracellular portion (aa 77‑855). The latter contains the following domains: SEA (aa 86‑201), two CUBs (aa 214‑334 and 340‑447), four LDLRAs (aa 452‑486, 487‑523, 524‑560, and 566‑603), and a serine protease (aa 615‑855). The physiological activation of the single‑chain zymogen requires the cleavage at the SEA domain within the ER or Golgi, association with HAI-1, which facilitates the transport of the protease to the cell surface, and auto‑cleavage at QAR-V(615)VGG (1). The activated matriptase is inhibited by HAI-1, and the resulting HAI-1 complex can be shed from the cell surface (1). R&D Systems recombinant human (rh) ST14 corresponds to the catalytic domain, and is inhibited effectively by rhHAI-1 and rhHAI-2A (Catalog # 1048‑PI and 1106‑PI).

References
  1. List, K. et al. (2006) Mol. Med. 12:1.
  2. Uhland, K. (2006) Cell. Mol. Life Sci. 63:2968.
  3. Netzel-Arnett, S. et al. (2006) J. Biol. Chem. 281:32941.
  4. Ahmed, S. et al. (2006) FEBS J. 273:615.
Entrez Gene IDs
6768 (Human); 19143 (Mouse); 114093 (Rat); 102117178 (Cynomolgus Monkey)
Alternate Names
EC 3.4.21; Epithin; HAI; Matriptase; Membrane-type serine protease 1; MTSP1; MT-SP1EC 3.4.21.109; prostamin; PRSS14; Serine protease 14; Serine protease TADG-15; SNC19; SNC19MTSP1; ST14; suppression of tumorigenicity 14 (colon carcinoma); suppression of tumorigenicity 14 (colon carcinoma, matriptase, epithin); suppressor of tumorigenicity 14 protein; TADG15; TADG-15; TMPRSS14; tumor associated differentially expressed gene 15 protein; Tumor-associated differentially-expressed gene 15 protein

Citations for Recombinant Human Matriptase/ST14 Catalytic Domain, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

15 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. PAR2 Activation on Human Kidney Tubular Epithelial Cells Induces Tissue Factor Synthesis, That Enhances Blood Clotting
    Authors: A Iyer, TLR Humphries, EP Owens, KN Zhao, PP Masci, DW Johnson, D Nikolic-Pa, GC Gobe, DP Fairlie, DA Vesey
    Frontiers in Physiology, 2021;12(0):615428.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  2. Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease
    Authors: S Kumari, M Dandamudi, S Rani, E Behaeghel, G Behl, D Kent, NJ O'Reilly, O O'Donovan, P McLoughlin, L Fitzhenry
    Pharmaceutics, 2021;13(6):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. Novel Ex Vivo Zymography Approach for Assessment of Protease Activity in Tissues with Activatable Antibodies
    Authors: B Howng, MB Winter, C LePage, I Popova, M Krimm, O Vasiljeva
    Pharmaceutics, 2021;13(9):.
    Species: Human
    Sample Types: Peptides
    Applications: Bioassay
  4. The activation fragment of PAR2 is elevated in serum from patients with rheumatoid arthritis and reduced in response to anti-IL6R treatment
    Authors: S Kalogera, Y He, AC Bay-Jensen, T Gantzel, S Sun, T Manon-Jens, MA Karsdal, CS Thudium
    Scientific Reports, 2021;11(1):24285.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  5. Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody
    Authors: M Geiger, KG Stubenrauc, J Sam, WF Richter, G Jordan, J Eckmann, C Hage, V Nicolini, A Freimoser-, M Ritter, ME Lauer, H Stahlberg, P Ringler, J Patel, E Sullivan, S Grau-Richa, S Endres, S Kobold, P Umaña, P Brünker, C Klein
    Nat Commun, 2020;11(1):3196.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Matriptase cleaves the amyloid-beta peptide 1-42 at Arg-5, Lys-16, and Lys-28
    Authors: LM Chen, KX Chai
    BMC Res Notes, 2019;12(1):5.
    Applications: Enzyme Assay
  7. Blocking the proteolytic activity of zymogen matriptase�with antibody-based inhibitors
    Authors: T Tamberg, Z Hong, D Schepper, S Skovbjerg, DM Dupont, L Vitved, CR Schar, K Skjoedt, LK Vogel, JK Jensen
    J. Biol. Chem., 2018;0(0):.
  8. A peptide-based approach to evaluate the adaptability of influenza A virus to humans based on its hemagglutinin proteolytic cleavage site
    Authors: MR Straus, GR Whittaker
    PLoS ONE, 2017;12(3):e0174827.
    Species: Virus - Influenza A
    Sample Types: Peptide
    Applications: Enzyme Assay
  9. A Selective Irreversible Inhibitor of Furin Does Not Prevent Pseudomonas Aeruginosa Exotoxin A-Induced Airway Epithelial Cytotoxicity
    PLoS ONE, 2016;11(7):e0159868.
    Species: Human
    Sample Types: Protein
    Applications: Enzyme Assay
  10. The HIV-1 gp41 ectodomain is cleaved by matriptase to produce a chemotactic peptide that acts through FPR2.
    Authors: Wood M, Cole A, Eade C, Chen L, Chai K, Cole A
    Immunology, 2014;142(3):474-83.
    Species: Human
    Sample Types: Peptide
    Applications: Bioassay
  11. High-affinity cyclic peptide matriptase inhibitors.
    Authors: Quimbar, Pedro, Malik, Uru, Sommerhoff, Christia, Kaas, Quentin, Chan, Lai Y, Huang, Yen-Hua, Grundhuber, Maresa, Dunse, Kerry, Craik, David J, Anderson, Marilyn, Daly, Norelle
    J Biol Chem, 2013;288(19):13885-96.
    Species: N/A
    Sample Types: Protein
    Applications: Enzyme Assay
  12. Simukunin from the salivary glands of the black fly Simulium vittatum inhibits enzymes that regulate clotting and inflammatory responses.
    Authors: Tsujimoto H, Kotsyfakis M, Francischetti IM
    PLoS ONE, 2012;7(2):e29964.
    Species: Black Fly
    Sample Types: Recombinant Protein
    Applications: Enzyme Assay
  13. Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome.
    Authors: Sales KU, Masedunskas A, Bey AL
    Nat. Genet., 2010;42(8):676-83.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Bioassay
  14. Proteolytic cleavage of human acid-sensing ion channel 1 by the serine protease matriptase.
    Authors: Clark EB, Jovov B, Rooj AK
    J. Biol. Chem., 2010;285(35):27130-43.
    Species: Xenopus
    Sample Types: Whole Cells
    Applications: Enzyme Assay
  15. Prostasin expression is regulated by airway surface liquid volume and is increased in cystic fibrosis.
    Authors: Myerburg MM, McKenna EE, Luke CJ, Frizzell RA, Kleyman TR, Pilewski JM
    Am. J. Physiol. Lung Cell Mol. Physiol., 2008;294(5):L932-41.
    Species: Human
    Sample Types: Peptide
    Applications: Bioassay

FAQs

  1. Catalog # 3946-SEB is formulated with 10% glycerol. Will the glycerol prevent it from freezing?

    • No, this protein in 10% glycerol will freeze at -20 C and -80 C. 

View all Proteins and Enzyme FAQs

Fluorogenic Peptide Substrates

Reviews for Recombinant Human Matriptase/ST14 Catalytic Domain, CF

Average Rating: 5 (Based on 3 Reviews)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Recombinant Human Matriptase/ST14 Catalytic Domain, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human Matriptase/ST14 Catalytic Domain, CF
By Anonymous on 12/11/2019
Application: Enzymatic activity in vitro
Reason for Rating: Matriptase catalytic domain has expected molecular mass and cleaves substrate at expected cleavage sites.

Substrate fusion proteins were purified from Drosophila S2R+ cells using anti-RFP magnetic agarose
Substrates were incubated with 0.1 ug matriptase at 37°C for one hour. Reaction was stopped by reducing/denaturing conditions. Samples were examined by SDS-PAGE/western blots and antibody stainings using respective antibodys.


Recombinant Human Matriptase/ST14 Catalytic Domain, CF
By Anonymous on 04/07/2019
Application: SDS-PAGE Control
Reason for Rating: Protein sample treated with Matriptase enzyme was cleaved after 30min incubation compared with control (untreated). Protein ladder ran to compare sizes

Recombinant Human Matriptase/ST14 Catalytic Domain, CF
By Anonymous on 07/31/2018
Application: Enzymatic activity in vitro

5nM of activated ST14 used